Amneal Pharmaceuticals Inc
F:2DT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amneal Pharmaceuticals Inc
F:2DT
|
US |
|
URU Metals Ltd
LSE:URU
|
CA |
|
G
|
GuocoLand (Malaysia) Bhd
KLSE:GUOCO
|
MY |
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale.
Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.
Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale.
Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.
Revenue Growth: Amneal reported record Q4 revenue of $814 million, up 11% year-on-year, and full-year 2025 revenue of $3 billion, up 8%.
Profitability: Q4 adjusted EBITDA grew 13% to $175 million, and full-year adjusted EBITDA rose 10% to $688 million. Adjusted EPS soared 43% to $0.83 for the year.
Guidance Raised: 2026 guidance calls for revenue of $3.05–3.15 billion (up 1%–4%), adjusted EBITDA of $720–760 million (up 5%–10%), and adjusted EPS of $0.93–1.03 (up 12%–24%).
Specialty Segment: CREXONT uptake exceeded expectations with 23,000 patients and >3% market share in its first year; expectation is to double revenue and market share again in 2026.
Biosimilars & Pipeline: Approval and launch momentum continues; biosimilar Xolair (with Celltrion) and further Omnipaque strengths expected to bolster growth.
GLP-1 Collaboration: Manufacturing buildout and partnership with Pfizer progressing well, positioning Amneal in a high-growth obesity/diabetes market.
Health Care Segment: 2026 revenue expected to decline from 2025's elevated level due to loss of exclusivity on a major product, but profitability to remain flat as focus shifts to higher-margin business.
